Engineered T cells designed to target and eliminate mesothelioma tumors
Official title: Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors
Funded at University of California, San Francisco · NIH-11056781 · Data updated 2026-11-12
This study is testing a new treatment for mesothelioma that uses specially designed T cells to better target and fight the cancer while protecting healthy cells, with the hope of improving outcomes for patients facing this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | April 4, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $666,268 |
| NIH project number | 5R01CA280440-03 |
| Project ID | NIH-11056781 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals diagnosed with mesothelioma who have limited treatment options.
✕Less likely to help
Patients with other types of cancer or those without mesothelioma may not benefit from this specific research.
What this research studies
This research focuses on developing a new type of engineered T cell therapy aimed at treating mesothelioma, a rare and aggressive cancer. The approach involves creating a dual antigen sensing system that allows T cells to precisely recognize and attack tumor cells while minimizing damage to normal tissues. By utilizing a novel antigen that is primarily found in mesothelioma, the therapy aims to enhance the effectiveness of T cell activation and reduce side effects. The research is designed to lead to clinical trials, potentially offering new hope for patients with this challenging condition.
Why it matters
Potential benefit: If successful, this research could provide a targeted and effective treatment option for patients suffering from mesothelioma.
How similar studies have gone: Previous research has shown promise in using engineered T cell therapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Roybal, Kole T — University of California, San Francisco
- Study coordinator: Roybal, Kole T
Related research
Other NIH-funded projects on the same topics.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Engineered CAR T immune cells targeting GPC3 for children's solid tumors
Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.
-
Boosting CAR T cell power in solid tumors by turning on transcription factors
A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Radio-triggered CAR-T cells to better control solid tumors
A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.
-
Understanding how cell behavior changes drive breast cancer in 3D cultures
Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.